My Pancreatic Cancer has recurred. How does this change my treatment choices, and are new targeted therapies using...

April 16, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Question asked:

My Pancreatic Cancer has recurred. How does this change my treatment choices, and are new targeted therapies using biomarkers (KRAS, BRCA1/2) available?

I need to pause here and address an important discrepancy in your medical information that affects how I can help you.

⚠️ CRITICAL CLARIFICATION NEEDED

Your medical profile shows prostate cancer (confirmed diagnosis with detailed staging: T3bN0MX, Gleason 4+3 to 4+5), but your question asks about pancreatic cancer recurrence.

These are two different cancers with completely different treatment approaches. Before I provide guidance, I need to understand:

1. Which cancer are you asking about?

  • Your prostate cancer (which appears to be your primary diagnosis based on your records)
  • A pancreatic cancer (which would be a separate diagnosis)
  • Both cancers (which would be a rare dual diagnosis)

2. Has your medical team confirmed pancreatic cancer?

  • If yes, this is important new information that changes everything about treatment planning
  • If this was a question you meant to ask about your prostate cancer, I can help clarify that

WHY THIS MATTERS

The biomarkers you've been tested for (BRCA1/2, ATM, TP53, PTEN, etc.) are relevant to prostate cancer treatment decisions, but pancreatic cancer uses different biomarkers (KRAS, BRCA1/2, PALB2, etc.) and has entirely different treatment pathways.

Your recent lab work shows prostate cancer with:

  • ATM mutation (abnormal) ✓ Relevant to prostate cancer treatment
  • TP53 mutation (abnormal) ✓ Relevant to prostate cancer treatment
  • BRCA2 testing (completed) ✓ Relevant to prostate cancer treatment

WHAT I CAN HELP WITH ONCE CLARIFIED

Once you clarify which cancer you're asking about, I can:

For prostate cancer: Explain how your ATM and TP53 mutations affect treatment options, discuss PARP inhibitor eligibility, and help you understand your 18-year treatment history

For pancreatic cancer: Explain biomarker-driven treatment options and clinical trial eligibility

For both: Help you formulate questions about managing multiple cancer diagnoses


Please clarify: Are you asking about recurrent prostate cancer, pancreatic cancer, or both? This will help me give you accurate, personalized educational information.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...

TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2